Pancreatic Ductal Adenocarcinoma Mice Lacking Mucin 1 Have a Profound Defect in Tumor Growth and Metastasis
| Autor: | Yong Y Lee, Lopamudra Das Roy, Dahlia M. Besmer, Sun-Il Hwang, Jorge Schettini, Jennifer M. Curry, Mahnaz Sahraei, Sandra J. Gendler, Pinku Mukherjee, Teresa L. Tinder |
|---|---|
| Rok vydání: | 2011 |
| Předmět: |
Cancer Research
medicine.medical_treatment Nerve Tissue Proteins Cell Growth Processes Article Metastasis Nestin Mice Intermediate Filament Proteins Tubulin Epidermal growth factor Pancreatic cancer Nitriles Butadienes medicine Animals Humans Neoplasm Metastasis Protein Kinase Inhibitors MUC1 Mice Knockout Platelet-Derived Growth Factor Epidermal Growth Factor biology Growth factor Cell Cycle Mucin-1 Cell cycle medicine.disease Mice Inbred C57BL Pancreatic Neoplasms Matrix Metalloproteinase 9 Oncology Tumor progression biology.protein Cancer research Mitogen-Activated Protein Kinases Platelet-derived growth factor receptor Carcinoma Pancreatic Ductal |
| Zdroj: | Cancer Research. 71:4432-4442 |
| ISSN: | 1538-7445 0008-5472 |
| Popis: | MUC1 is overexpressed and aberrantly glycosylated in more than 60% of pancreatic ductal adenocarcinomas. The functional role of MUC1 in pancreatic cancer has yet to be fully elucidated due to a dearth of appropriate models. In this study, we have generated mouse models that spontaneously develop pancreatic ductal adenocarcinoma (KC), which are either Muc1-null (KCKO) or express human MUC1 (KCM). We show that KCKO mice have significantly slower tumor progression and rates of secondary metastasis, compared with both KC and KCM. Cell lines derived from KCKO tumors have significantly less tumorigenic capacity compared with cells from KCM tumors. Therefore, mice with KCKO tumors had a significant survival benefit compared with mice with KCM tumors. In vitro, KCKO cells have reduced proliferation and invasion and failed to respond to epidermal growth factor, platelet-derived growth factor, or matrix metalloproteinase 9. Further, significantly less KCKO cells entered the G2–M phase of the cell cycle compared with the KCM cells. Proteomics and Western blotting analysis revealed a complete loss of cdc-25c expression, phosphorylation of mitogen-activated protein kinase (MAPK), as well as a significant decrease in nestin and tubulin-α2 chain expression in KCKO cells. Treatment with a MEK1/2 inhibitor, U0126, abrogated the enhanced proliferation of the KCM cells but had minimal effect on KCKO cells, suggesting that MUC1 is necessary for MAPK activity and oncogenic signaling. This is the first study to utilize a Muc1-null PDA mouse to fully elucidate the oncogenic role of MUC1, both in vivo and in vitro. Cancer Res; 71(13); 4432–42. ©2011 AACR. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|